FY2025 Earnings Forecast for NRXP Issued By HC Wainwright

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Analysts at HC Wainwright issued their FY2025 earnings estimates for NRx Pharmaceuticals in a research report issued on Monday, September 8th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.57) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2026 earnings at $0.42 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.67).

Several other research firms also recently weighed in on NRXP. BTIG Research reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to MarketBeat.com, NRx Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Trading Down 5.7%

NASDAQ:NRXP opened at $2.97 on Thursday. The company’s 50-day moving average price is $2.81 and its 200-day moving average price is $2.55. The company has a market cap of $58.84 million, a P/E ratio of -1.33 and a beta of 1.63. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of NRXP. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $61,000. Geode Capital Management LLC raised its stake in shares of NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the period. Finally, Anson Funds Management LP raised its stake in shares of NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after acquiring an additional 993,401 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.